Genetic predisposing factors to bronchopulmonary dysplasia: preliminary data from a multicentre study

Somaschini, Marco; Castiglioni, Emanuela; Volonteri, Chiara; Cursi, Marco; Ferrari, María Rosa; Carrera, Paola

doi:10.3109/14767058.2012.714995

Cited by 14 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We need to continue to seek insights into the basic mechanisms of neonatal lung development, injury and repair in order to identify novel targets for intervention. In addition, ongoing research focused on genetic determinants of BPD may lead to targeted therapeutic approaches based on host factors and specific patient genetic and epigenetic makeup 99 . Finally, development of prediction tools for BPD based on perinatal and postnatal risk factors may prove very useful in stratifying patients by risk category in future RCTs of new interventions 100 .…”

Section: Resultsmentioning

confidence: 99%

An update on pharmacologic approaches to bronchopulmonary dysplasia

Ghanta

Leeman

Christou

2013

Seminars in Perinatology

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most prevalent long-term morbidity in surviving extremely preterm infants and is linked to increased risk of reactive airways disease, pulmonary hypertension, post-neonatal mortality, and adverse neurodevelopmental outcomes. BPD affects approximately 20% of premature newborns, and up to 60% of premature infants born before 26 completed weeks of gestation. It is characterized by the need for assisted ventilation and/or supplemental oxygen at 36 weeks’ postmenstrual age. Approaches to prevention and treatment of BPD have evolved with improved understanding of its pathogenesis. This review will focus on recent advancements and detail current research in pharmacotherapy for BPD. The evidence for both current and potential future experimental therapies will be reviewed in detail. As our understanding of the complex and multifactorial pathophysiology of BPD changes, research into these current and future approaches must continue to evolve.

show abstract

Section: Resultsmentioning

confidence: 99%

An update on pharmacologic approaches to bronchopulmonary dysplasia

Ghanta

Leeman

Christou

2013

Seminars in Perinatology

View full text Add to dashboard Cite

show abstract

“…These models could then be refined for example by adding genetic susceptibility as a predictor [63]. However, more research is needed to determine which of the suggested multiple candidate genes will increase accuracy of a prediction model [64]. Another improvement in the clinical prediction models could come from using birth weight Z scores in addition to gestational age instead of combining gestational age and birth weight in the model.…”

Section: Discussionmentioning

confidence: 99%

Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study

et al. 2013

View full text Add to dashboard Cite

BackgroundBronchopulmonary dysplasia (BPD) is a common complication of preterm birth. Very different models using clinical parameters at an early postnatal age to predict BPD have been developed with little extensive quantitative validation. The objective of this study is to review and validate clinical prediction models for BPD.MethodsWe searched the main electronic databases and abstracts from annual meetings. The STROBE instrument was used to assess the methodological quality. External validation of the retrieved models was performed using an individual patient dataset of 3229 patients at risk for BPD. Receiver operating characteristic curves were used to assess discrimination for each model by calculating the area under the curve (AUC). Calibration was assessed for the best discriminating models by visually comparing predicted and observed BPD probabilities.ResultsWe identified 26 clinical prediction models for BPD. Although the STROBE instrument judged the quality from moderate to excellent, only four models utilised external validation and none presented calibration of the predictive value. For 19 prediction models with variables matched to our dataset, the AUCs ranged from 0.50 to 0.76 for the outcome BPD. Only two of the five best discriminating models showed good calibration.ConclusionsExternal validation demonstrates that, except for two promising models, most existing clinical prediction models are poor to moderate predictors for BPD. To improve the predictive accuracy and identify preterm infants for future intervention studies aiming to reduce the risk of BPD, additional variables are required. Subsequently, that model should be externally validated using a proper impact analysis before its clinical implementation.

show abstract

“…Many potential risk factors have been identified for the development of BPD (see Fig. 1) including lower gestational age, 9 low birth weight for gestational age, 10 white race, 11 male gender, 12 genetic factors 13 and other common sequelae during the neonatal period such as intraventricular haemorrhage, necrotizing enterocolitis, patent ductus arteriosis or sepsis. [14][15][16] The current consensus definition determines BPD at 36 weeks post-menstrual age (PMA) in infants born less than 32 weeks gestation who required supplementary oxygen for at least respiratory support at 36 weeks PMA.…”

Section: Definition and Risk Factors For Bpdmentioning

confidence: 99%

Lung function following very preterm birth in the era of ‘new’ bronchopulmonary dysplasia

2015

View full text Add to dashboard Cite

One of the most significant complications of preterm birth is bronchopulmonary dysplasia (BPD). The pathophysiology of BPD has changed in recent years as advances in neonatal care have led to increased survival of smaller, more preterm, infants who display alterations to alveolar and pulmonary microvascular development. It is becoming clear that infants with 'new' BPD experience lung disease that persists into later childhood, however, the oldest of these children are just now entering young adulthood and therefore the longer term pulmonary implications remain unknown. The role of lung function testing in the identification and subsequent management of patients with lung disease resulting from a neonatal classification of BPD is reviewed based on the underlying pathophysiology of the disease.

show abstract

Genetic predisposing factors to bronchopulmonary dysplasia: preliminary data from a multicentre study

Cited by 14 publications

References 9 publications

An update on pharmacologic approaches to bronchopulmonary dysplasia

An update on pharmacologic approaches to bronchopulmonary dysplasia

Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study

Lung function following very preterm birth in the era of ‘new’ bronchopulmonary dysplasia

Contact Info

Product

Resources

About